MTOR and hepatocellular carcinoma: Activation of the PI3K-Akt kinase signaling pathway through the insulin or IGF receptors (such as IGFR1) results in disruption of the mammalian target of rapamycin (mTOR) pathway, which occurs in about 40% to 50% of cases of HCC, thus promoting carcinogenesis110.